# ClinicalTrials.gov record NCT07226765

> PeptideScanner retained ClinicalTrials.gov record NCT07226765 at 2026-07-30T16:19:03.046Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07226765-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07226765-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct07226765-maridebart-cafraglutide-v1.json
- Content SHA-256: `913198185bff84775197068c1a4f4e530c536dd32dd5c9944d1df1432a15f732`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT07226765 ([`ctg-observation-nct07226765-2026-06-12-7e841bc432b4`](#source-ctg-observation-nct07226765-2026-06-12-7e841bc432b4))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07226765 at 2026-07-30T16:19:03.046Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07226765-2026-06-12-7e841bc432b4`](#source-ctg-observation-nct07226765-2026-06-12-7e841bc432b4))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07226765 at 2026-07-30T16:19:03.046Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07226765-2026-06-12-7e841bc432b4`](#source-ctg-observation-nct07226765-2026-06-12-7e841bc432b4))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07226765-2026-06-12-7e841bc432b4`](#source-ctg-observation-nct07226765-2026-06-12-7e841bc432b4))

## Sources

<a id="source-ctg-observation-nct07226765-2026-06-12-7e841bc432b4"></a>
- **ClinicalTrials.gov record NCT07226765 · retained source version 2026-06-12:7e841bc432b47bbab67050e3d0fad0b2eb875d796eedd4f2f6deedf391de2317** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07226765) (`ctg-observation-nct07226765-2026-06-12-7e841bc432b4`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07226765." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct07226765-maridebart-cafraglutide-v1.json SHA-256: 913198185bff84775197068c1a4f4e530c536dd32dd5c9944d1df1432a15f732.